Kornimate/medical-research-clean huggingface dataset:
effects of snags with and without pilates in lumbar disc bulge patients

Conditions: Lumbar Disc Herniation; Lumbar Radiculopathy

Summary: the aim of this study is to compare the effects of sustained natural apophyseal glides with and without pilates on pain, range of motion and disability in patients with lumbar disc bulge.

lumbar disc disease may occur when a disc in the low back area of the spine bulges or herniates between the bony areas of the spine. lumbar disk disease causes lower back pain and leg pain and weakness that is made worse by movement and activity. lumbar disc bulge is typically managed through a multidimensional approach that integrates various therapeutic techniques aimed at reducing symptoms and enhancing functional outcomes. the use of snags has been shown to produce positive results such as decreased pain levels and increased mobility in previous studies. overall physical conditioning can be improved by using a holistic approach that consists of controlled movements combined with breathing techniques and mindfulness. in order to treat lumbar disc bulge patients more effectively, it is important to understand how use and efficacy differ when applying snags alone versus together with pilates. delving into how combining snags and pilates affects lumbar disc bulge patients contributes to an expanding body of proof advocating for a multimodal treatment.

Eligibility criteria:
inclusion criteria: * patient of both gender under the age of 40-60 year. * unilateral radiating pain through the course of sciatic nerve * a duration of pain of at least 3 months * restricted lumbar range of motion. * subjects who can understand the instructions and are willing to participate in the study * positive slump test with positive pain location and positive pain descriptors. * passive lumbar extension if the patient experiences severe low back pain or if there is a feeling of heaviness on the lower back or a feeling as though the lower back were about to 'come off' the test is considered positive. * straight leg raise slr test positive when it evokes radiating pain along the course of the sciatic nerve and below the knee between 30 and 70 degrees of hip flexion exclusion criteria: * history of trauma, dislocation and subluxation of lower extremity. * rheumatoid arthritis * systemic diseases such as blood coagulation disorders, chronic pain syndrome, cancer, allergies fibromyalgia, systemic lupus erythematous, and psoriatic arthritis. * lumbar spine surgery patients. * malignancy * neurologic disorders (e.g., trigeminal neuralgia or occipital neuralgia) * clinical diagnosis of lumbar bilateral radiculopathy or myelopathy * history of previous physical therapy intervention for the lumbar region in last 6 months

Keywords: disability lumbar radiculopathy low back pain endurance
studying genes to identify melanoma in patients in iceland and their family members

Conditions: Melanoma (Skin)

Summary: rationale: studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer. purpose: this clinical trial is studying genes to identify melanoma in patients in iceland and their family members.

objectives: * assess the feasibility of iceland genomics corporation (uvs) to identify melanoma in multiple-case families, individuals with multiple tumors, and selected additional family members in iceland. * assess the feasibility of mutation detection using sequencing and hplc. * determine uvs' ability to create datasets with demographic, epidemiologic and molecular data. outline: participants and patients undergo blood collection and complete lifestyle questionnaires. all patients and population-based controls have dna samples sequenced for mc1r. demographic and epidemiologic data on all study participants is collected. sequencing of the major melanoma susceptibility genes cfdkn2a, cdk4, and mc1r is also performed.

Eligibility criteria:
disease characteristics: * patients diagnosed with melanoma and selected family members are eligible to participate * must live in iceland patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: melanoma recurrent melanoma stage i melanoma stage ii melanoma stage iii melanoma stage iv melanoma
rajavtihi neuronal adult stem cells project

Conditions: Alzheimer's Disease; Parkinson's Disease; Multiple Sclerosis

Summary: to study the success of oligodendrocyte progenitor cell culture project in rajavithi hospital to identify an unlimited clone human neuronal progenitor stem cells from the human brain in the biomolecular research center. this study aims to produce the reproductive clone of neuronal development protocols and advance projects. neuronal cells such as pyramidal cells, oligodendrocyte, and dopaminergic neuron differentiation protocol/projects for treatment of alzheimer's disease, multiple sclerosis, and parkinson's disease respectively in next phase of clinical trials.


Eligibility criteria:
inclusion criteria: * patients who have elective craniotomy or. * patients who have elective ventriculostomy surgery or. * patients who have elective muscle biopsy or nerve biopsy. * patient who have emergency craniectomy for life threatening from emergency medical and surgical conditions such as brain herniation or head injury exclusion criteria: * central nervous system infection for example tuberculous or any bacterial infection, viral infection, fungal infection. * central nervous system tumor, malignancy and metastasis.

Keywords: adult progenitor stem cells alzheimer's disease parkinson's disease multiple sclerosis
clinical study on a new flowable composite as a restorative in adult teeth

Conditions: Dental Caries

Summary: study hypothesis: a new, low polymerization stress flowable composite performs no differently to a conventional, highly filled composite filling material when used as a restorative in small cavities in back teeth. study will evaluate the clinical performance of a low shrinking flowable composite filling material, compared with a conventional, highly filled composite restorative when used to permanently fill small cavities in molar and premolar teeth in adult patients.

the study will evaluate clinical performance of a low shrink flowable composite filling material and compare it with a conventional, highly filled composite. the study materials will be used to restore small cavities in molar and premolar teeth in adult patients.

Eligibility criteria:
inclusion criteria: * 19 years or older * must give written consent * be in good general health * be available for required follow-up visits * have at least 28 teeth exclusion criteria: * has rampant, uncontrolled caries * has advanced, untreated periodontal disease * heavy use of smoking tobacco (2 packs or equivalent a day)or chewing tobacco * has systemic or local disorders that contra-indicate the dental procedures needed in this study * has evidence of xerostomia * has evidence of severe bruxing or clenching, or in need of temporomandibular joint (tmj) related therapy * is pregnant at time of screening or tooth restoration * has known sensitivity to acrylates or related materials

Keywords: small class i molar and premolar low stress flowable composite adult restoration small caries lesions
optic nerve sheath diameter in patients undergoing palatoplasty

Conditions: Cleft Palate

Summary: the purpose of this study is to evaluate the change of the optic nerve sheath diameter according to the change of the neck position in pediatric patients undergoing palatoplasty.

palatoplaty is performed under neck extension in patients with cleft palate. the purpose of this study is to evaluate the effect of neck extension on the ultrasonographic optic nerve sheath diameter during palatoplasty.

Eligibility criteria:
inclusion criteria: * patients who have undergone a palatoplasty with cleft palate and who are 6 months or older and under 24 months * patients who agree to voluntarily participate in this study * patients with asa class 1-2 exclusion criteria: * history of diagnosis of neurologic or ophthalmic disease * history of neurosurgery or ophthalmic surgery * patients who refused to participate in clinical studies
pharmacokinetics study of mci-186 in subjects with mild or moderate renal impairment

Conditions: Renal Impairment; Healthy

Summary: to assess the pharmacokinetics of mci-186 after a single intravenous infusion of 30mg/hour in subjects with mild or moderate renal impairment compared to subjects with normal renal function.


Eligibility criteria:
inclusion criteria: all subjects * able to provide written informed consent to participate in this study after reading the icf * subjects is able to understand and willing to cooperate and comply with the protocol restrictions and requirements * a body weight of ≥45 kg in males or ≥40 kg in females and a body mass index ranging from 18 to 30 kg/m2 renal impaired subjects (in addition) * subjects with mild renal impairment defined as egfr 60-89 ml/min/1.73m2 and subjects with moderate renal impairment defined as egfr 30-59 ml/min/1.73m2 * chronic and stable renal impairment healthy subjects (in addition) * subject with normal renal function defined as egfr≥90 ml/min/1.73m2 * good health and free from clinically significant illness or disease exclusion criteria: all subjects * presence or history of severe allergy to food, or any medicinal product or relevant excipient that is of clinical significance * subjects were previously administered mci-186 * positive urine drug screen (if not due to concomitant medication) or alcohol test * history of alcohol abuse or drug abuse * presence of active infection requiring antibiotics * positive test for human immunodeficiency virus (hiv) antigen/antibody, hepatitis b surface antigen (hbsag), or hepatitis c virus antibody (hcvab) renal impairment subject (in addition) * acute renal failure * history of renal transplantation * aspartate aminotransferase (ast) activity, or an alanine aminotransferase (alt) activity of at least 3 times the upper limit of normal (uln) range * uncontrolled, or untreated hypertension defined as systolic blood pressure (sbp)\>180 mmhg and/or diastolic blood pressure (dbp)\>110 mmhg * start of any new medication or new any changes to a current dosage healthy subject (in addition) * history or presence of any renal disease * uncontrolled, or untreated hypertension defined as systolic blood pressure (sbp)\>160 mmhg and/or diastolic blood pressure (dbp)\>100 mmhg
sequence of endocrine therapy in advanced luminal breast cancer (sequel-breast)

Conditions: Neoplasm, Breast; Congenital, Familial and Genetic Disorders

Summary: the study is a nationwide, multicenter single-arm phase 2 study. the current phase 2 study investigates the efficacy of the combination of fulvestrant and alpelisib directly after progression on fulvestrant (either in first or second line, with or without previous use of cdk4/6-inhibitor) in patients with hr+ her2- advanced breast cancer with pik3ca mutated tumors. all eligible patients must have progressive disease on fulvestrant as latest treatment line. previous treatment with a cdk4/6 inhibitor in first or second line is obligatory. after progressive disease is confirmed, it is important to continue fulvestrant (without cdk4/6 inhibition) during the screening period awaiting study enrollment. after study enrollment all participants will be treated with alpelisib and fulvestrant beyond progression. follow-up time will be until progression or death or until a different oncolytic treatment has started (in case no progressive disease during previous fulvestrant and alpelisib treatment has been documented). should participants discontinue due to reasons other than progression or death (e.g. toxicity), then they should still be evaluated for disease progression every 8 weeks as per protocol until progression, unless they do not wish to proceed with these screenings, or receive a different oncolytic treatment.


Eligibility criteria:
inclusion criteria: * adult women and men (≥ 18 years of age) with proven diagnosis of adenocarcino-ma of the breast withlocoregional recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent andfor whom chemotherapy is not clinically indicated * estrogen receptor (er) expression \>10% and/or progesterone receptor (pr) expression \>10% breast cancerbased on local la-boratory results. tumor must be her2- as defined by asco-cap guidelines * patients must have progressed on fulvestrant as a preceding treatment line (as first or second line therapy) * previous treatment with a cdk4/6 inhibitor in the advanced setting * the presence of an activating pik3ca mutation * evaluable disease\* as defined per recist v.1.1 * eastern cooperative oncology group (ecog) performance status (ps) 0, 1 or 2 exclusion criteria: * patients with advanced, symptomatic, visceral spread, who are at risk of life-threatening complications in theshort term * known active uncontrolled or symptomatic cns metastases, carcinomatous meningitis, or leptomeningealdisease as indicated by clinical symptoms, cerebral edema, and/or progressive growth * prior treatment with a pi3k /akt/mtor inhibitor * type 1 diabetes or uncontrolled type 2 diabetes (hba1c \> 68 mmol/mol) * clinically significant, uncontrolled heart disease and/or recent cardiac events

Keywords: hormone receptor positive her2 negative breast cancer pik3ca-activated mutation
the impact of smoking on the prognosis of elderly surgical patients

Conditions: Delirium, Postoperative

Summary: postoperative delirium is a common complication that frequently occurs in elderly patients after surgery. it not only increases the length of hospital stays and healthcare costs but also raises the incidence of postoperative cognitive dysfunction and even mortality. however, the underlying mechanisms of its onset are not yet fully understood. evidence suggests that smoking can lead to gut microbiota dysbiosis and metabolic dysfunction, and the gut microbiota and its metabolites play a crucial role in cognitive function through the gut-brain axis. yet, no studies have reported whether smoking could affect the occurrence of postoperative delirium and the quality of postoperative recovery through the gut microbiota. this study aims to observe the incidence of postoperative delirium and the postoperative recovery quality scores between smokers and non-smokers.

after obtaining approval from the ethics committee, patients are recruited, informed of the trial process and potential risks, and their informed consent is obtained and signed. according to the who definition, patients are classified into smokers (defined as those who smoke more than one cigarette per day continuously or cumulatively for six months; more than four times a week but averaging less than one cigarette per day) and non-smokers (never smoked). fecal and blood samples are collected from both groups of patients preoperatively, and perioperative data is gathered. postoperatively, an uninformed observer assesses the patients for delirium and recovery quality.

Eligibility criteria:
inclusion criteria: * age \>60 years; * american society of anesthesiologists (asa) preoperative anesthesia classification asa grades i and ii; * undergoing elective surgery; * patients and their families are able to understand and complete various scoring scales and voluntarily sign informed consent. exclusion criteria: * mini-mental state examination (mmse) score \<23; * preoperative biochemical tests indicate renal dysfunction or active liver disease; * history of definite neurological or psychiatric disorders or history of taking corresponding medications before surgery; * history of alcohol abuse or drug dependency; * taking antidepressant medications; * american society of anesthesiologists (asa) preoperative anesthesia classification \> grade ii.
brazilian reality of urinary bladder cancers - bra-bladder

Conditions: Urothelial Carcinoma; Non Muscle Invasive Bladder Cancer; Muscle-invasive Bladder Cancer

Summary: a national, multicenter, non-randomized, retrospective, observational study (real-world evidence-rwe) aimed at analyzing clinical presentation profiles and demographic characteristics of patients with early urothelial bladder cancer (high-risk non-muscle invasive and localized muscle-invasive) treated with standard therapies in national cancer treatment reference centers within the last 6 years (between 2017 and 2022).

urothelial carcinoma has several histological types, extensive genetic diversity and a wide array of risk factors related to disease development. moreover, the treatment effectiveness may be widely impacted by factors such as age, previous comorbidities, socio-economic factors, late diagnosis and access to treatment. in the last decade, the treatment profile has evolved worldwide with the incorporation of new technologies, however, there is no data on brazilian reality in this period. in a continent-sized country and such heterogeneous health services as brazil, preparing such knowledge becomes more important and challenging. this paper proposed to describe early urothelial carcinoma presentation pattern and treatment in brazilian population (high-risk non-muscle-invasive and localized muscle-invasive) in several sites spread throughout the national territory. thus, data will be generated to provide a more appropriate understanding of the current landscape and, consequently, the better design of public policies to face this disease.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old; * diagnosis of high-risk non-muscle invasive urothelial carcinoma, defined as: * t1 tumor and/or high-grade lesion (g3) and/or presence of cis. * multifocal relapsed tumor and with at least one large lesion (diameter ≥ 3 cm); * diagnosis of early muscle-invasive urothelial bladder carcinoma (ct2, ct3 or ct4a n0); * consent to participate in the study. exclusion criteria: * low-risk non-muscle invasive urothelial carcinoma (single lesion, pta and low-grade); * locally advanced muscle-invasive urothelial carcinoma (suspected lymph node impairment in staging imaging tests) or metastatic at diagnosis; * bladder carcinoma with non-urothelial histology (adenocarcinoma, squamous-cell carcinoma or small cell carcinoma);

Keywords: bladder cancer, rwe
point-of-care echocardiography to assess impact of dynamic cardiac function, renal and cardiac biomarkers in cirrhosis with refractory ascites

Conditions: Cirrhosis, Liver; Acute-On-Chronic Liver Failure; Refractory Ascites; Ascites; Acute Kidney Injury

Summary: point-of-care echocardiography (poc-echo) is used to determine left ventricular systolic and diastolic dysfunction (lvdd), inferior vena cava (ivc) dynamics and volume status in cirrhosis and acute-on-chronic liver failure aclf accurately. we will assess ivc dynamics, lv systolic function \[lv ejection fraction (ef) \& cardiac output (co)\], and diastolic dysfunction (e/e', e' and e/a ratio) and urinary biomarkers (cystatin c and ngal) in patients with cirrhosis and refractory ascites.

the decrease in systemic vascular resistance (svr) and redistribution of blood volume with reduced intravascular volume compartment and third space fluid losses. systemic vasodilatation is compensated by an increase in cardiac output (co) in the initial stages of compensated cirrhosis. however, as the stage of liver cirrhosis progresses to decompensation, more prominent arterial vasodilatation and reduced svr leads to a fall in co. thus, the cardiac homeostat is reset in a cirrhotic hyperdynamic circulation, wherein an increased heart rate, and therefore, increased cardiac output will no longer be able to compensate for the reduced mean arterial pressure (map), and decreased blood volumes in central venous territories.18 consequent activation of vasoconstrictor systems including renin-angiotensin-aldosterone, vasopressin and the sympathetic nervous system comes into play to maintain the intravascular blood volume and pressure. these compensatory pathways cause an increase in sodium and water retention resulting in refractory ascites and hepatorenal syndrome (hrs). in critically ill patients with cirrhosis, the limited cardiac reserve is further stressed, ccm and heart failure may be diagnosed for the first time when the patient develops sepsis or septic shock. point-of-care echocardiography (poc-echo) is used to determine left ventricular systolic and diastolic dysfunction (lvdd), inferior vena cava (ivc) dynamics and volume status in cirrhosis accurately. we will assess ivc dynamics, lv systolic function \[lv ejection fraction (ef) \& cardiac output (co)\], and diastolic dysfunction (e/e', e' and e/a ratio) in patients with cirrhosis aclf and refractory ascites definition of ccm is as per updated ccmc criteria of 2020.

Eligibility criteria:
inclusion criteria: * cirrhosis of any etiology * patient with refractory ascites exclusion criteria: * hepatocellular carcinoma * patients with active variceal bleeding * hiv or severe immunocompromised state * chronic kidney disease (ckd) on renal replacement therapy (rrt), * previous transjugular intra hepatic portosystemic shunt (tips) * porto-pulmonary hypertension, * coronary artery disease * congenital or valvular heart disease * prosthetic cardiac valves

Keywords: ascites cirrhotic cardiomyopathy acute kidney injury
treatment persistence among patients with overactive bladder: a retrospective secondary data analysis in asia oceania

Conditions: Overactive Bladder (OAB)

Summary: the purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in australia, south korea and taiwan. this study will also assess the persistence to the overall overactive bladder (oab) treatments of a patient, regardless of treatment discontinuation or switch to other oab medications.

this study is entirely descriptive using secondary medical claim and pharmacy prescription data. no formal comparisons between users of mirabegron and antimuscarinic will be made. furthermore, no a priori hypothesis testing is intended.

Eligibility criteria:
inclusion criteria: * patient with a new prescription of the index medication within the index period; * patient received orally administered monotherapy for oab on index date. exclusion criteria: * patient with prior dispensing record of the index medication during the pre-index period; * patient received onabotulinumtoxin a and/or surgical intervention as part of the oab treatment between the pre index and post-index period; * patient diagnosed with stress incontinence (international classification of diseases-10 (icd-10) n39.3 or equivalent) or had dispensing record of medication for stress incontinence (duloxetine) before index date; * patient with urinary tract infection (icd-10 n30.0 or equivalent) (for national health insurance research database (nhird) and health insurance review and assessment (hira) database) or a co-prescription of any antibiotics (for nostradata) on index date.

Keywords: darifenacin fesoterodine trospium solifenacin oxybutynin tolterodine betmiga ym178 mirabegron overactive bladder propiverine antimuscarinics oab imidafenacin